of Ubiquitin Therapy of Sensorineural Hearing Loss in Children by Elzbieta Reron, Gabriel Turowski & Eugeniusz Olszewski
biotherapy has been administered of 20 patients aged from 5
to 14 with bilateral progressive sensorineural hearing loss
(SNHL) of unknown etiology lasting from several months to three
years. An extract from calf thymuses-Thymus Factor (TFX) was
applied intramuscularly in a daily dose 10 mg of active substance.
Initially TFX was given four times a week, then three times
a week and finally twice a week within 12 to 18 months. In a
group of 14 patients with bilateral progressive SNHL all children
have shown in audiometric examinations an improvement of about
20 to 75 dBnHL within the range of frequencies relevant for
understanding speech and moreover, increased speech discrimination.
The obtained improvement in hearing enabled four patients from
the group to give up hearing aids that they had been using for
one to three years. In six other patients from SNHL group the
obtained hearing improvement of about 20 to 25 dBnHL within
the range of intensity from 70 to 90 dB has not essentially
affected improvement in speech understanding, it has however,
enabled to use hearing aids with significantly less amplification
at the input of the hearing aid. Encouraging results of the
effective treatment of bilateral and progressive SNHL with unknown
etiology substantiate the continuation of ubiquitin biotherapy
in these cases. In the same time one may suggest it may become
a new strategy in the treatment.